
1. IDENTIFICATION OF THE MATERIAL AND SUPPLIER

1.1 Product identifier

Product name TRI-SOLFEN TOPICAL ANAESTHETIC & ANTISEPTIC SOLUTION FOR PAIN RELIEF IN LAMBS AND CALVES
Synonyms TRI-SOLFEN

1.2 Uses and uses advised against

Uses ANALGESIC • ANTIMICROBIAL
A local anaesthetic and antiseptic gel spray for pain relief on lambs following tail docking, on lambs and calves during and following castration and as an adjunct therapy for calves after disbudding using hot iron cautery.
ACVM Number: A011409

1.3 Details of the supplier of the product

Supplier name DECHRA VETERINARY PRODUCTS NZ LTD
Address PO Box 1604, Paraparaumu Beach, 5252, NEW ZEALAND
Telephone 0800 473 838
Email info.nz@dechra.com
Website <http://www.dechra.co.nz/>

1.4 Emergency telephone numbers

Emergency 0800 764 766 (National Poisons Centre NZ)

2. HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture

HAZARDOUS ACCORDING TO NZ ENVIRONMENTAL PROTECTION AUTHORITY CRITERIA

Physical Hazards

Not classified as a Physical Hazard

Health Hazards

Acute Toxicity: Oral: Category 5
Carcinogenicity: Category 2
Germ Cell Mutagenicity: Category 2
Respiratory Sensitisation: Category 1
Serious Eye Damage / Eye Irritation: Category 2A
Skin Corrosion/Irritation: Category 3
Skin Sensitisation: Category 1
Specific Target Organ Toxicity (Repeated Exposure): Category 2

Environmental Hazards

Aquatic Toxicity (Chronic): Category 2
Terrestrial Vertebrates Ecotoxicity: Category 3

2.2 GHS Label elements

Signal word DANGER

Pictograms

PRODUCT NAME TRI-SOLFEN TOPICAL ANAESTHETIC & ANTISEPTIC SOLUTION FOR PAIN RELIEF IN LAMBS AND CALVES

Hazard statements

H303	May be harmful if swallowed.
H316	Causes mild skin irritation.
H317	May cause an allergic skin reaction.
H319	Causes serious eye irritation.
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled.
H341	Suspected of causing genetic defects.
H351	Suspected of causing cancer.
H373	May cause damage to organs through prolonged or repeated exposure.
H411	Toxic to aquatic life with long lasting effects.
H433	Harmful to terrestrial vertebrates.

Prevention statements

P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P264	Wash thoroughly after handling.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection/hearing protection.
P284	Wear respiratory protection.

Response statements

P301 + P312	IF SWALLOWED: Call a POISON CENTRE or doctor/physician if you feel unwell.
P302 + P352	IF ON SKIN: Wash with plenty of water.
P304 + P340	IF INHALED: Remove person to fresh air and keep comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P313	IF exposed or concerned: Get medical advice/ attention.
P321	Specific treatment is advised - see first aid instructions.
P362 + P364	Take off contaminated clothing and wash it before reuse.
P391	Collect spillage.

Storage statements

P405	Store locked up.
------	------------------

Disposal statements

P501	Dispose of contents/container in accordance with relevant regulations.
------	--

2.3 Other hazards

No information provided.

3. COMPOSITION/ INFORMATION ON INGREDIENTS

3.1 Substances / Mixtures

Ingredient	CAS Number	EC Number	Content
LIGNOCAINE HYDROCHLORIDE	6108-05-0	612-079-4	1 to <5%
BUPIVACAINE HYDROCHLORIDE	14252-80-3	241-917-8	0.1 to <0.5%
CETRIMIDE	8044-71-1	617-073-5	0.1 to 0.5%
SODIUM METABISULPHITE	7681-57-4	231-673-0	0.1 to <0.5%
(-)-EPINEPHRINE(+)BITARTRATE	51-42-3	200-097-1	0.001 to <0.005%
NON HAZARDOUS INGREDIENTS	Not Available	Not Available	Remainder

4. FIRST AID MEASURES

4.1 Description of first aid measures

Eye	If in eyes, hold eyelids apart and flush continuously with running water. Continue flushing until advised to stop by a Poisons Information Centre, a doctor, or for at least 15 minutes.
Inhalation	If inhaled, remove from contaminated area. To protect rescuer, use an Air-line respirator or Self Contained Breathing Apparatus (SCBA). Be aware of possible explosive atmospheres. Apply artificial respiration if not breathing. Give oxygen if available.
Skin	If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water.

PRODUCT NAME TRI-SOLFEN TOPICAL ANAESTHETIC & ANTISEPTIC SOLUTION FOR PAIN RELIEF IN LAMBS AND CALVES

Ingestion For advice, contact the National Poisons Centre on 0800 764 766 (0800 POISON) or +643 479 7248 or a doctor (at once).

First aid facilities None allocated.

4.2 Most important symptoms and effects, both acute and delayed

See Section 11 for more detailed information on health effects and symptoms.

4.3 Immediate medical attention and special treatment needed

Treat symptomatically.

5. FIRE FIGHTING MEASURES

5.1 Extinguishing media

Use an extinguishing agent suitable for the surrounding fire.

5.2 Special hazards arising from the substance or mixture

Non flammable. May evolve oxides of carbon and nitrogen and hydrogen bromide gas when heated to decomposition.

5.3 Advice for firefighters

Evacuate area and contact emergency services. Toxic gases may be evolved in a fire situation. Remain upwind and notify those downwind of hazard. Wear full protective equipment including Self Contained Breathing Apparatus (SCBA) when combating fire. Use waterfog to cool intact containers and nearby storage areas.

5.4 Hazchem code

None allocated.

6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Wear Personal Protective Equipment (PPE) as detailed in section 8 of the SDS. Clear area of all unprotected personnel. Ventilate area where possible. Contact emergency services where appropriate.

6.2 Environmental precautions

Prevent product from entering drains and waterways.

6.3 Methods of cleaning up

Contain spillage, then cover / absorb spill with non-combustible absorbent material (vermiculite, sand, or similar), collect and place in suitable containers for disposal.

6.4 Reference to other sections

See Sections 8 and 13 for exposure controls and disposal.

7. HANDLING AND STORAGE

7.1 Precautions for safe handling

Before use carefully read the product label. Use of safe work practices are recommended to avoid eye or skin contact and inhalation. Observe good personal hygiene, including washing hands before eating. Prohibit eating, drinking and smoking in contaminated areas.

7.2 Conditions for safe storage, including any incompatibilities

Store in a cool, dry, well ventilated area, removed from incompatible substances, heat or ignition sources and foodstuffs. Ensure containers are adequately labelled, protected from physical damage and sealed when not in use. Store below 30°C. Avoid moisture.

7.3 Specific end uses

No information provided.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

8.1 Control parameters

Exposure standards

Ingredient	Reference	TWA		STEL	
		ppm	mg/m ³	ppm	mg/m ³
Sodium metabisulphite	WES [NZ]	--	5	--	--

Biological limits

No biological limit values have been entered for this product.

8.2 Exposure controls

Engineering controls Avoid inhalation. Use in well ventilated areas. Where an inhalation risk exists, mechanical extraction ventilation is recommended.

PPE

- Eye / Face** Wear splash-proof goggles.
- Hands** Wear rubber or PVC gloves.
- Body** When using large quantities or where heavy contamination is likely, wear coveralls.
- Respiratory** At high vapour levels, wear Self Contained Breathing Apparatus (SCBA) or an Air-line respirator.



9. PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

Appearance	BLUE LIQUID
Odour	SLIGHT ODOUR
Flammability	NON FLAMMABLE
Flash point	NOT RELEVANT
Boiling point	> 100°C
Melting point	NOT AVAILABLE
Evaporation rate	NOT AVAILABLE
pH	2 to 3
Vapour density	NOT AVAILABLE
Relative density	NOT AVAILABLE
Solubility (water)	SOLUBLE
Vapour pressure	NOT RELEVANT
Upper explosion limit	NOT RELEVANT
Lower explosion limit	NOT RELEVANT
Partition coefficient	NOT AVAILABLE
Autoignition temperature	NOT AVAILABLE
Decomposition temperature	NOT AVAILABLE
Viscosity	285 cPs (Approximately)
Explosive properties	NOT AVAILABLE
Oxidising properties	NOT AVAILABLE
Odour threshold	NOT AVAILABLE

9.2 Other information

Density	1.03 g/cm ³ @ 20°C
---------	-------------------------------

10. STABILITY AND REACTIVITY

10.1 Reactivity

Carefully review all information provided in sections 10.2 to 10.6.

PRODUCT NAME TRI-SOLFEN TOPICAL ANAESTHETIC & ANTISEPTIC SOLUTION FOR PAIN RELIEF IN LAMBS AND CALVES

10.2 Chemical stability

Stable under recommended conditions of storage.

10.3 Possibility of hazardous reactions

Polymerization will not occur.

10.4 Conditions to avoid

Avoid heat, sparks, open flames and other ignition sources.

10.5 Incompatible materials

Incompatible with oxidising agents (e.g. hypochlorites) and acids (e.g. nitric acid).

10.6 Hazardous decomposition products

May evolve oxides of carbon and nitrogen and hydrogen bromide gas when heated to decomposition.

11. TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute toxicity This product is used in veterinary applications. May be harmful if swallowed. Use safe work practices to avoid eye contact, prolonged skin contact and ingestion. Refer to medical doctor/specialist for advice regarding adverse side effects.

Information available for the ingredients:

Ingredient	Oral LD50	Dermal LD50	Inhalation LC50
BUPIVACAINE HYDROCHLORIDE	18 mg/kg (rabbit)	--	--
SODIUM METABISULPHITE	1540 mg/kg (rat)	> 2000 mg/kg (rat)	> 5.5 mg/l/4hrs (rat)
(-)-EPINEPHRINE(+)-BITARTRATE	4 mg/kg (mouse)	--	--

Skin Causes mild skin irritation. Contact may result in irritation, redness, pain and rash.

Eye Causes serious eye irritation. Contact may result in irritation, lacrimation, pain and redness.

Sensitisation May cause an allergic skin reaction. May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Mutagenicity Suspected of causing genetic defects.

Carcinogenicity Suspected of causing cancer.

Reproductive Not classified as a reproductive toxin.

STOT - single exposure Over exposure may result in dizziness, drowsiness, weakness, fatigue, breathing difficulties and unconsciousness.

STOT - repeated exposure May cause damage to organs through prolonged or repeated exposure if swallowed.

Aspiration Not classified as causing aspiration.

12. ECOLOGICAL INFORMATION

12.1 Toxicity

Toxic to aquatic life with long lasting effects. Harmful to terrestrial vertebrates.

12.2 Persistence and degradability

No information provided.

12.3 Bioaccumulative potential

No information provided.

12.4 Mobility in soil

No information provided.

12.5 Other adverse effects

No additional environmental data is currently available for this product.

13. DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Waste disposal	For small amounts, absorb with sand or similar and dispose of to an approved landfill site. Contact the manufacturer/supplier for additional information (if required). Ensure that appropriate personal protective equipment is used during disposal.
Legislation	Dispose of in accordance with relevant local legislation.

14. TRANSPORT INFORMATION

CLASSIFIED AS A DANGEROUS GOOD ACCORDING TO LAND TRANSPORT RULE: DANGEROUS GOODS 2005; NZS 5433:2012, UN, IMDG OR IATA



	LAND TRANSPORT (NZS 5433)	SEA TRANSPORT (IMDG / IMO)	AIR TRANSPORT (IATA / ICAO)
14.1 UN Number	3082	3082	3082
14.2 Proper Shipping Name	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Cetrimide)	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Cetrimide)	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Cetrimide)
14.3 Transport hazard class	9	9	9
14.4 Packing Group	III	III	III

14.5 Environmental hazards

Not a Marine Pollutant.

14.6 Special precautions for user

Hazchem code	None allocated.
EmS	F-A, S-F

15. REGULATORY INFORMATION

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Approval code	HSR100759
Group standard	Veterinary Medicines (Non-dispersive Open System Application) Group Standard 2020
Inventory listings	AUSTRALIA: AIIC (Australian Inventory of Industrial Chemicals) All components are listed on AIIC, or are exempt. EUROPE: EINECS (European Inventory of Existing Chemical Substances) All components are listed on EINECS, or are exempt. NEW ZEALAND: NZIoC (New Zealand Inventory of Chemicals) All components are listed on the NZIoC inventory, or are exempt.

16. OTHER INFORMATION

Additional information	EXPOSURE STANDARDS - TIME WEIGHTED AVERAGES: Exposure standards are established on the premise of an 8 hour work period of normal intensity, under normal climatic conditions and where a 16 hour break between shifts exists to enable the body to eliminate absorbed contaminants. In the following circumstances, exposure standards must be reduced: Strenuous work conditions; hot, humid climates; high altitude conditions; extended shifts (which increase the exposure period and shorten the period of recuperation).
-------------------------------	---

PRODUCT NAME TRI-SOLFEN TOPICAL ANAESTHETIC & ANTISEPTIC SOLUTION FOR PAIN RELIEF IN LAMBS AND CALVES

WORKPLACE CONTROLS AND PRACTICES: Unless a less toxic chemical can be substituted for a hazardous substance, **ENGINEERING CONTROLS** are the most effective way of reducing exposure. The best protection is to enclose operations and/or provide local exhaust ventilation at the site of chemical release. Isolating operations can also reduce exposure. Using respirators or protective equipment is less effective than the controls mentioned above, but is sometimes necessary.

PERSONAL PROTECTIVE EQUIPMENT GUIDELINES:

The recommendation for protective equipment contained within this report is provided as a guide only. Factors such as form of product, method of application, working environment, quantity used, product concentration and the availability of engineering controls should be considered before final selection of personal protective equipment is made.

HEALTH EFFECTS FROM EXPOSURE:

It should be noted that the effects from exposure to this product will depend on several factors including: form of product; frequency and duration of use; quantity used; effectiveness of control measures; protective equipment used and method of application. Given that it is impractical to prepare a report which would encompass all possible scenarios, it is anticipated that users will assess the risks and apply control methods where appropriate.

Abbreviations

ACGIH	American Conference of Governmental Industrial Hygienists
CAS #	Chemical Abstract Service number - used to uniquely identify chemical compounds
CCID	Chemical Classification and Information Database (HSNO)
CNS	Central Nervous System
EC No.	EC No - European Community Number
EMS	Emergency Schedules (Emergency Procedures for Ships Carrying Dangerous Goods)
EPA	Environmental Protection Authority [New Zealand]
GHS	Globally Harmonized System
HSNO	Hazardous Substances and New Organisms
IARC	International Agency for Research on Cancer
LC50	Lethal Concentration, 50% / Median Lethal Concentration
LD50	Lethal Dose, 50% / Median Lethal Dose
mg/m ³	Milligrams per Cubic Metre
OEL	Occupational Exposure Limit
pH	relates to hydrogen ion concentration using a scale of 0 (high acidic) to 14 (highly alkaline).
ppm	Parts Per Million
STEL	Short-Term Exposure Limit
STOT-RE	Specific target organ toxicity (repeated exposure)
STOT-SE	Specific target organ toxicity (single exposure)
TLV	Threshold Limit Value
TWA	Time Weighted Average

Report status

This document has been compiled by RMT on behalf of the manufacturer, importer or supplier of the product and serves as their Safety Data Sheet ('SDS').

It is based on information concerning the product which has been provided to RMT by the manufacturer, importer or supplier or obtained from third party sources and is believed to represent the current state of knowledge as to the appropriate safety and handling precautions for the product at the time of issue. Further clarification regarding any aspect of the product should be obtained directly from the manufacturer, importer or supplier.

While RMT has taken all due care to include accurate and up-to-date information in this SDS, it does not provide any warranty as to accuracy or completeness. As far as lawfully possible, RMT accepts no liability for any loss, injury or damage (including consequential loss) which may be suffered or incurred by any person as a consequence of their reliance on the information contained in this SDS.

Prepared by

Risk Management Technologies
5 Ventnor Ave, West Perth
Western Australia 6005
Phone: +61 8 9322 1711
Fax: +61 8 9322 1794
Email: info@rmt.com.au
Web: www.rmtglobal.com

[End of SDS]